

New aromatic bisabolane derivatives with anti-obesity activity

Margarida Costa ^{1*}, Laura Coello ², Ralph Urbatzka ³, Marta Pérez ², Margrét Thorsteinsdóttir¹

¹ Faculty of Pharmaceutical Sciences, University of Iceland, Hofsvallagata 53, 107 Reykjavik, Iceland; costa.anamarg@gmail.com

² Research & Development Department, PharmaMar S.A., Pol. Ind. La Mina Norte, Avda. de los Reyes 1, 28770 Colmenar Viejo (Madrid), Spain

³ Interdisciplinary Centre of Marine and Environmental Research (CIIMAR/CIMAR), University of Porto, Avenida General Norton de Matos, s/n, 4450-208 Matosinhos, Portugal

* Correspondence: margreth@hi.is; Tel.: +354-895-4761

Table of content	Pages
Figure S1 – Fresh sponge used in this study.	2
Figures S2-S3 - 1D NMR spectra for Compound 1 in CDCl ₃	3-4
Figure S4 - HRESIMS spectrum for Compound 1	5
Figures S5-S7 - 1D NMR and g-COSY spectra for Compound 2 in CDCl ₃	5-8
Figure S8 - HRESIMS spectrum for Compound 2	9
Figures S9-S15 - 1D and 2D NMR spectra for Compound 3 in CDCl ₃	10-16
Figure S16 - HRESIMS spectrum for Compound 3	17
Figures S17-S23 - 1D and 2D NMR spectra for Compound 4 in CDCl ₃	18-24
Figure S24 - HRESIMS spectrum for Compound 4	25
Figures S25-S26 - 1D and spectra for Compound 5 in CDCl ₃	26-27
Figure S27 - HRESIMS spectrum for Compound 5	28
Figures S28-S34 - 1D and 2D NMR spectra for Compound 6 in CH ₃ OD	29-35
Figure S35 - HRESIMS spectrum for Compound 6	36
Figures S36-S43 - 1D and 2D NMR spectra for Compound 7 in CDCl ₃	37-44
Figure S44 - HRESIMS spectrum for Compound 7	45
Figure S45 – MS fragmentation pattern for Compound 7	46



Figure S1 – Fresh sponge used for this study. The sample was morphologically identified as *Myrmekioderma* sp..




Figure S2 – ^1H -NMR spectrum for **Compound 1** (400 MHz, CDCl_3).




Figure S3 – ^{13}C -NMR spectrum for **Compound 1** (100 MHz, CDCl_3).




Figure S4 - HRESIMS spectrum for **Compound 1**.




Figure S5 – ^1H -NMR spectrum for Compound 2 (400 MHz, (CDCl_3) .




Figure S6 – ^{13}C -NMR spectrum for Compound 2 (100 MHz, CDCl_3).




Figure S7 – *g*-COSY spectrum for Compound 2 (100 MHz, CDCl_3).




Figure S8 - HRESIMS spectrum for **Compound 2**.




Figure S9 – ¹H-NMR spectrum for Compound 3 (400 MHz, CDCl₃).




Figure S10 – DEPT and ^{13}C -NMR spectra for Compound 3 (100 MHz, CDCl_3).




Figure S11 - *g*-COSY spectrum for **Compound 3** (400 MHz, CDCl_3).




Figure S12 - TOCSY spectrum for Compound 3 (400 MHz, CDCl_3).




Figure S13 - *g*-HMQC spectrum for **Compound 3** (400 MHz, CDCl_3).




Figure S14 - g -HMBC spectrum for Compound 3 (400 MHz, CDCl_3).




Figure S15 - NOESY spectrum for **Compound 3** (400 MHz, CDCl_3).




Figure S16 - (-)-HRESIMS spectrum for Compound 3.




Figure S17 – ^1H -NMR spectrum for Compound 4 (400 MHz, CDCl_3).




Figure S18 ^{13}C -NMR spectra for **Compound 4** (100 MHz, CDCl_3).




Figure S19 - *g*-COSY spectrum for Compound 4 (400 MHz, CDCl_3).




Figure S20 - TOCSY spectrum for Compound 4 (400 MHz, CDCl_3).




Figure S21 - *g*-HMQC spectrum for Compound 4 (400 MHz, CDCl_3).




Figure S22 - *g*-HMBC spectrum for **Compound 4** (400 MHz, CDCl_3).




Figure S23 - NOESY spectrum for Compound 4 (400 MHz, CDCl_3).




Figure S24 - HRESIMS spectrum for Compound 4.




Figure 25 – ^1H -NMR spectrum for Compound 5 (400 MHz, CDCl_3).




Figure 26 – DEPT and ^{13}C -NMR spectra for Compound 5 (100 MHz, CDCl_3).




Figure S27 - HRESIMS spectrum for Compound 5.




Figure S28 – ^1H -NMR spectrum for Compound 6 (400 MHz, CD_3OD).




Figure S29 – DEPT and ^{13}C -NMR spectra for **Compound 6** (100 MHz, CD_3OD).




Figure S30 - *g*-COSY spectrum for Compound 6 (400 MHz, CD_3OD).




Figure S31 - TOCSY spectrum for Compound 6 (400 MHz, CD_3OD).




Figure S32 - g -HMQC spectrum for **Compound 6** (400 MHz, CD_3OD).




Figure 33 - g-HMBC spectrum for Compound 6 (400 MHz, CD_3OD).




Figure 34 - NOESY spectrum for **Compound 6** (400 MHz, CD_3OD).




Figure S35 - HRESIMS spectrum for **Compound 6**.




Figure S36 – ^1H -NMR spectrum for Compound 7 (400 MHz, CDCl_3).




Figure S37 – ¹³C-NMR spectrum for Compound 7 (400 MHz, CDCl₃).




Figure S38 - *g*-COSY spectrum for Compound 7 (400 MHz, CDCl_3).




Figure S39 - TOCSY spectrum for **Compound 7** (400 MHz, CDCl_3).




Figure S40 - *g*-HMQC spectrum for Compound 7 (400 MHz, CDCl₃).




Figure S41 - *g*-HMBC spectrum for Compound 7 (400 MHz, CDCl_3).




Figure S42 - NOESY spectrum for **Compound 7** (400 MHz, CDCl_3).




Figure S43 – Close up of NOESY spectrum for **Compound 7** (400 MHz, CDCl_3).




Figure S44 - HRESIMS spectrum for Compound 7.




Figure S45 - Compound 7 MS fragmentation ions induced by ESI (negative ionization mode).